Robert Tansley

Sortera Bio is harnessing Deep Screening to address the toughest challenges in biologics discovery. Visit our website to learn more.

T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.

Our mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction by leveraging a deep mechanistic understanding of mitochondrial biology. Mitochondria are essential energy-converting cellular organelles found in nearly every cell type throughout the body. Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondrial dysfunction also plays an important role in more common diseases, including aging-related disorders. At Pretzel, we are developing first-in-class therapeutics that can address mitochondrial dysfunction at its roots. By taking aim at the genetic drivers of mitochondrial dysfunction, we believe our approach could be effective across a wide range of diseases which lack meaningful treatment options today.

PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. We are using the highest quality science to make the therapies our pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human drug development, we are applying the cutting edge of science to bring breakthroughs for the animals we love and care for. PetMedix is taking the experience of its founding team, and decades of human clinical research, to build platforms that generate fully species-specific, naturally-generated therapeutic antibodies. These platforms have been designed to generate a repertoire of antibodies as diverse as the companion animal immune systems on which they are based. These platforms can then be used to develop a broad pipeline of our own veterinary medicines to target under-served clinical areas that represent excellent market opportunities. We are actively recruiting so please get in touch if you wish to join our hard-working and talented team.

Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers.

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

CMR Surgical is a global medical devices company dedicated to transforming surgery with Versius®, a next-generation surgical robot. CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care. To find out more, or to join our world-class team please visit our website.

MORPHOGEN-IX LIMITED is a biotechnology company based out of MONETA BUILDING BABRAHAM RESEARCH CAMPUS, CAMBRIDGE, United Kingdom.

STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023. STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.

ABCODIA LIMITED is a clinical stage company engaged in the development of novel tests for the early detection of cancer. We specialise in the development of software medical devices that can accurately interpret change in blood based biomarkers in a way that leads to the detection of cancer in the early stages when symptoms are not yet apparent. Our current focus is ovarian cancer, and our lead product is the ROCA® Test

Congenica is a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale. We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide. Congenica’s Platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care. Our products and services are consolidated on one single scalable, automated analysis and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights and pathogen surveillance. Congenica was founded based on pioneering work at the Wellcome Trust Sanger Institute and the UK NHS. We are the exclusive clinical decision support partner for the NHS Genomic Medicine Service and have a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies.

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

Sortera Bio is harnessing Deep Screening to address the toughest challenges in biologics discovery. Visit our website to learn more.

The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation. BIA is a trade association with 600+ member companies including: - Start-ups, biotechnology and innovative life science companies - Pharmaceutical and technological companies - Universities, research centres, tech transfer offices, incubators and accelerators - A wide range of life science service providers: investors, lawyers, IP consultants, IR agencies BIA is the key thought leader for the sector – working across a wide range of related issues, including policy, finance, science, regulatory, legal and talent on topics including engineering biology and techbio.

T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.

Our mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction by leveraging a deep mechanistic understanding of mitochondrial biology. Mitochondria are essential energy-converting cellular organelles found in nearly every cell type throughout the body. Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondrial dysfunction also plays an important role in more common diseases, including aging-related disorders. At Pretzel, we are developing first-in-class therapeutics that can address mitochondrial dysfunction at its roots. By taking aim at the genetic drivers of mitochondrial dysfunction, we believe our approach could be effective across a wide range of diseases which lack meaningful treatment options today.

PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. We are using the highest quality science to make the therapies our pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human drug development, we are applying the cutting edge of science to bring breakthroughs for the animals we love and care for. PetMedix is taking the experience of its founding team, and decades of human clinical research, to build platforms that generate fully species-specific, naturally-generated therapeutic antibodies. These platforms have been designed to generate a repertoire of antibodies as diverse as the companion animal immune systems on which they are based. These platforms can then be used to develop a broad pipeline of our own veterinary medicines to target under-served clinical areas that represent excellent market opportunities. We are actively recruiting so please get in touch if you wish to join our hard-working and talented team.